tiprankstipranks
Trending News
More News >

Verve Therapeutics price target raised to $24 from $18 at Guggenheim

Guggenheim raised the firm’s price target on Verve Therapeutics (VERV) to $24 from $18 and keeps a Buy rating on the shares, arguing that the top-line Heart-2 Phase 1b data for VERVE-102 “provided a strikingly clean win.” Following the data, the firm is increasing its view on the odds of success to 75% from 60%, the analyst noted.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue